Pub Date : 2022-03-11DOI: 10.14218/jerp.2022.00005
Yan Zhang, Q. Qiu, Jing-feng Xu, Hong Yang, Bing Sun
{"title":"Pre-clinical Exploratory Evaluation of Mab806-derived Immunotoxin in Targeting Solid Tumors with High Potency and Selectivity Towards EGFRvIII","authors":"Yan Zhang, Q. Qiu, Jing-feng Xu, Hong Yang, Bing Sun","doi":"10.14218/jerp.2022.00005","DOIUrl":"https://doi.org/10.14218/jerp.2022.00005","url":null,"abstract":"","PeriodicalId":73746,"journal":{"name":"Journal of exploratory research in pharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43368321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-11DOI: 10.14218/jerp.2022.00002
Walid Yeddes, Hammami Majdi, Hamza Gadhoumi, Taycir Grati Affes, S. N. Mohamed, W. Aidi Wannes, Moufida Saidani-Tounsi
{"title":"Optimizing Ethanol Extraction of Rosemary Leaves and Their Biological Evaluations","authors":"Walid Yeddes, Hammami Majdi, Hamza Gadhoumi, Taycir Grati Affes, S. N. Mohamed, W. Aidi Wannes, Moufida Saidani-Tounsi","doi":"10.14218/jerp.2022.00002","DOIUrl":"https://doi.org/10.14218/jerp.2022.00002","url":null,"abstract":"","PeriodicalId":73746,"journal":{"name":"Journal of exploratory research in pharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46542021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Delivery System for Targeted Drug Therapy in Chronic Diseases","authors":"Yuan-Qi Jiang, Jin-Peng Chen, Yu Dong, Fu-Jun Zhou, Cheng-Wang Tian, Chang-Qing Chen","doi":"10.14218/jerp.2021.00052","DOIUrl":"https://doi.org/10.14218/jerp.2021.00052","url":null,"abstract":"","PeriodicalId":73746,"journal":{"name":"Journal of exploratory research in pharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43626156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-03-01Epub Date: 2021-10-12DOI: 10.14218/jerp.2021.00014
Paula A Ambrose, Wendy A Goodman
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in Wuhan, China, in late 2019. Responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic, SARS-CoV-2 is one of three structurally similar beta-coronaviruses that can cause a strong upregulation of cytokines referred to as cytokine release syndrome (CRS). Unresolved CRS leads to respiratory symptoms, including pneumonia, and in more severe cases, acute respiratory distress syndrome (ARDS). Although COVID-19 is widely known for these hallmark respiratory symptoms, it also impacts the gut, causing gastrointestinal (GI) tract inflammation and diarrhea. COVID-19's GI symptoms may be due to the high intestinal expression of angiotensin converting enzyme-2 receptors, which are for the binding of SARS-CoV-2 viral particles. Reports have shown that SARS-CoV-2 can be passed through fecal matter, with one study finding that 48.1% of COVID-19 patients expressed viral SARS-CoV-2 mRNA in their stool. Given that the GI tract is a target tissue affected by COVID-19, this causes concern for those with underlying GI pathologies, such as inflammatory bowel disease (IBD). Regrettably, there have been only limited studies on the impact of COVID-19 on gut health, and the impact of COVID-19 on intestinal inflammation among IBD patients remains unclear. In particular, questions regarding susceptibility to SARS-CoV-2 infection, clinical impact of COVID-19 on IBD, and the potential influence of age, sex, and immunosuppressant medications are still poorly understood. An improved understanding of these issues is needed to address the unique risks of COVID-19 among IBD patients, as well as the potential impact of SARS-CoV-2 on the host intestinal microbiota.
{"title":"Impact of COVID-19 on Patients with Inflammatory Bowel Disease.","authors":"Paula A Ambrose, Wendy A Goodman","doi":"10.14218/jerp.2021.00014","DOIUrl":"10.14218/jerp.2021.00014","url":null,"abstract":"<p><p>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in Wuhan, China, in late 2019. Responsible for the ongoing coronavirus disease 2019 (COVID-19) pandemic, SARS-CoV-2 is one of three structurally similar beta-coronaviruses that can cause a strong upregulation of cytokines referred to as cytokine release syndrome (CRS). Unresolved CRS leads to respiratory symptoms, including pneumonia, and in more severe cases, acute respiratory distress syndrome (ARDS). Although COVID-19 is widely known for these hallmark respiratory symptoms, it also impacts the gut, causing gastrointestinal (GI) tract inflammation and diarrhea. COVID-19's GI symptoms may be due to the high intestinal expression of angiotensin converting enzyme-2 receptors, which are for the binding of SARS-CoV-2 viral particles. Reports have shown that SARS-CoV-2 can be passed through fecal matter, with one study finding that 48.1% of COVID-19 patients expressed viral SARS-CoV-2 mRNA in their stool. Given that the GI tract is a target tissue affected by COVID-19, this causes concern for those with underlying GI pathologies, such as inflammatory bowel disease (IBD). Regrettably, there have been only limited studies on the impact of COVID-19 on gut health, and the impact of COVID-19 on intestinal inflammation among IBD patients remains unclear. In particular, questions regarding susceptibility to SARS-CoV-2 infection, clinical impact of COVID-19 on IBD, and the potential influence of age, sex, and immunosuppressant medications are still poorly understood. An improved understanding of these issues is needed to address the unique risks of COVID-19 among IBD patients, as well as the potential impact of SARS-CoV-2 on the host intestinal microbiota.</p>","PeriodicalId":73746,"journal":{"name":"Journal of exploratory research in pharmacology","volume":"7 1","pages":"37-44"},"PeriodicalIF":0.0,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b2/84/nihms-1774288.PMC9373928.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9375922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Application of NLRP3 Inflammasome-related Modulators in Sepsis","authors":"Ming-he Yang, Chunlei Duan, Shanshou Liu, Jian-Gang Xie","doi":"10.14218/jerp.2021.00055","DOIUrl":"https://doi.org/10.14218/jerp.2021.00055","url":null,"abstract":"","PeriodicalId":73746,"journal":{"name":"Journal of exploratory research in pharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46634494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-02-10DOI: 10.14218/jerp.2021.00061
Apostolos Zarros
{"title":"Computational Drug Screening in COVID-19 Drug Repurposing Research: Encouraging Findings and Limitations","authors":"Apostolos Zarros","doi":"10.14218/jerp.2021.00061","DOIUrl":"https://doi.org/10.14218/jerp.2021.00061","url":null,"abstract":"","PeriodicalId":73746,"journal":{"name":"Journal of exploratory research in pharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48800777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-30DOI: 10.14218/jerp.2021.00036
Xue-Shan Huang, Zheng Zhu, Xiao-ling Li, Hui Luo, Lianxiang Luo
{"title":"Ferroptosis-related Gene Model and Nomogram Predict the Prognosis and Immune Microenvironment for Hepatocellular Carcinoma","authors":"Xue-Shan Huang, Zheng Zhu, Xiao-ling Li, Hui Luo, Lianxiang Luo","doi":"10.14218/jerp.2021.00036","DOIUrl":"https://doi.org/10.14218/jerp.2021.00036","url":null,"abstract":"","PeriodicalId":73746,"journal":{"name":"Journal of exploratory research in pharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45337704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-29DOI: 10.14218/jerp.2021.00051
K. Aykaç, E. Başaran
Background and objectives: Epilepsy is a neural disorder that occurs because of a disruption in neural conduc-tions in various parts of the brain and is mainly characterized by seizures, pensive gaze, involuntary mimics, contractions, meaningless speeches, repetitive movements, and loss of consciousness. The serious side effects of conventional drug delivery systems due to high applied doses, low transition rates to the brain, and limitations of drug application during seizures result in the urgent need for novel drug delivery systems for the enhanced treatment of epilepsy. Methods: In this study, Lacosamide was selected because of its high therapeutic dose, which is due to its low transition to the target site. Microneedle patches were formulated by micromolding of polymers of carboxy-methyl cellulose (CMC) and Eudragit S 100 (ES100) for a unique route for applications to reduce the applied dose to minimize the severe side effects. This strategy enhanced brain transition via the nasal route and over-came the blood-brain barrier (BBB) to minimize the applied dose. Characterization studies were performed in detail. Results: The results revealed that the releases of Lacosamide extended to 96 h with ES100 microneedle patches. In contrast, CMC microneedles released almost all the active ingredients within 1 h due to the hydrophilic nature of the polymer. Stability studies indicated that the formulations were stable at 25 ± 2°C (60 ± 5% Relative Humid-ity; RH), 40 ± 2°C (75 ± 5% RH) and 5 ± 3°C for 6 months. Conclusions: By considering the film like structures, polymeric microneedle patches have the potential for Lacosa-mide delivery through the unconventional nasal route for the improved treatment of epilepsy.
背景和目的：癫痫是一种因大脑各部分神经传导中断而发生的神经疾病，主要表现为癫痫发作、沉思凝视、非自愿模仿、收缩、无意义讲话、重复运动和意识丧失。传统药物递送系统由于应用剂量高、向大脑的转化率低以及癫痫发作期间药物应用的局限性而产生的严重副作用，导致迫切需要用于增强癫痫治疗的新型药物递送系统。方法：在本研究中，选择拉卡酰胺是因为它的治疗剂量高，这是因为它向靶位点的转化率低。微针贴片是通过对羧甲基纤维素（CMC）和Eudragit S 100（ES100）的聚合物进行微成型来配制的，这是一种独特的应用途径，可以减少应用剂量，最大限度地减少严重的副作用。这种策略通过鼻腔途径增强了大脑的过渡，并越过血脑屏障（BBB），以最大限度地减少所施加的剂量。详细进行了表征研究。结果：ES100微针贴片的拉沙酰胺释放时间延长至96小时。相反，由于聚合物的亲水性，CMC微针在1小时内释放出几乎所有的活性成分。稳定性研究表明，制剂在25±2°C（60±5%相对湿度；RH）、40±2°C.（75±5%RH）和5±3°C下稳定6个月。结论：考虑到膜状结构，聚合物微针贴片有可能通过非常规鼻腔途径递送Lacosa酰胺，从而改善癫痫的治疗。
{"title":"Formulation and Characterization of Lacosamide-loaded Polymeric Microneedles","authors":"K. Aykaç, E. Başaran","doi":"10.14218/jerp.2021.00051","DOIUrl":"https://doi.org/10.14218/jerp.2021.00051","url":null,"abstract":"Background and objectives: Epilepsy is a neural disorder that occurs because of a disruption in neural conduc-tions in various parts of the brain and is mainly characterized by seizures, pensive gaze, involuntary mimics, contractions, meaningless speeches, repetitive movements, and loss of consciousness. The serious side effects of conventional drug delivery systems due to high applied doses, low transition rates to the brain, and limitations of drug application during seizures result in the urgent need for novel drug delivery systems for the enhanced treatment of epilepsy. Methods: In this study, Lacosamide was selected because of its high therapeutic dose, which is due to its low transition to the target site. Microneedle patches were formulated by micromolding of polymers of carboxy-methyl cellulose (CMC) and Eudragit S 100 (ES100) for a unique route for applications to reduce the applied dose to minimize the severe side effects. This strategy enhanced brain transition via the nasal route and over-came the blood-brain barrier (BBB) to minimize the applied dose. Characterization studies were performed in detail. Results: The results revealed that the releases of Lacosamide extended to 96 h with ES100 microneedle patches. In contrast, CMC microneedles released almost all the active ingredients within 1 h due to the hydrophilic nature of the polymer. Stability studies indicated that the formulations were stable at 25 ± 2°C (60 ± 5% Relative Humid-ity; RH), 40 ± 2°C (75 ± 5% RH) and 5 ± 3°C for 6 months. Conclusions: By considering the film like structures, polymeric microneedle patches have the potential for Lacosa-mide delivery through the unconventional nasal route for the improved treatment of epilepsy.","PeriodicalId":73746,"journal":{"name":"Journal of exploratory research in pharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42856934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-24DOI: 10.14218/jerp.2021.00034
I. Ahmad, Rahman Ali, Monyck Jeane dos Santos Lopes, C. H. Steinmetz, F. Haq
{"title":"Artemisia annua L. and Its Derivatives: Their Antiviral Effects on COVID-19 and Possible Mechanisms","authors":"I. Ahmad, Rahman Ali, Monyck Jeane dos Santos Lopes, C. H. Steinmetz, F. Haq","doi":"10.14218/jerp.2021.00034","DOIUrl":"https://doi.org/10.14218/jerp.2021.00034","url":null,"abstract":"","PeriodicalId":73746,"journal":{"name":"Journal of exploratory research in pharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44550924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-01-20DOI: 10.14218/jerp.2021.00044
Kwong‐Fai Wong
{"title":"Identification of Bioactive Components in QingFeiPaiDu Decoction for Treatment of COVID-19 by Network Pharmacology","authors":"Kwong‐Fai Wong","doi":"10.14218/jerp.2021.00044","DOIUrl":"https://doi.org/10.14218/jerp.2021.00044","url":null,"abstract":"","PeriodicalId":73746,"journal":{"name":"Journal of exploratory research in pharmacology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48785922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号